Multiple Myeloma
From the Journals
CRISPR-engineered T cells may be safe for cancer, but do they work?
All three patients who received CRISPR-engineered T cells in a phase 1 trial experienced cancer progression but minimal toxicity.
From the Journals
Start of myeloma therapy may be delayed for women, minorities
Timeliness of treatment should be addressed urgently because of potential effects on disease morbidity, quality of life, and survival.
Conference Coverage
Inhibitor appears to strengthen anti-BCMA CAR T cells in myeloma patients
ORLANDO – All 10 patients responded to anti-BCMA CAR T-cell therapy, including 3 patients who had previously failed BCMA-directed therapy.
Conference Coverage
D-RVd for frontline myeloma looks robust in GRIFFIN trial update
ORLANDO – The depth of response has improved over time, though further follow-up is needed to evaluate the durability of response and progression-...
Conference Coverage
Myeloma patients over age 70 can benefit from auto-HC transplant
ORLANDO – Researchers said all myeloma patients should be referred a transplant center, regardless of age.
Conference Coverage
Bispecific CAR T-cells yield high response rate in relapsed/refractory myeloma
ORLANDO – Duration of response, manageable safety support further investigation of dual-targeted strategy, according to investigator.
Conference Coverage
High complete response rate seen with novel CAR-T for myeloma
ORLANDO – A CAR T product targeting B-cell maturation antigen, one of several in development, was associated with a 100% overall response rate.
Conference Coverage
ASH preview: Key themes include tackling CAR T obstacles, sickle cell advances, VTE
New findings take aim at CAR T-cell therapy-related obstacles and highlight potential new paths forward.
From the Journals
Early lenalidomide may delay progression of smoldering myeloma
Researchers said the findings from the phase 3 study support early treatment as the new standard of care in patients with high-risk smoldering...
Latest News
Foundation launches direct-to-patient registry in multiple myeloma
The registry is designed to give information back to patients, but physicians may be able to use the database to identify high-risk patients and...
From the Journals
Levofloxacin prophylaxis improves survival in newly diagnosed myeloma
Levofloxacin looks like a promising addition to therapy, but the researchers cautioned that antibiotic resistance must be considered.